SKN reports strongest quarter of sales to date
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Australian owned and operated natural skin care company, Skin Elements Limited (ASX:SKN) has provided a positive December quarterly report showing growth, product development and increased sales — including its strongest quarter of sales to date totalling A$219,000.
That figure represents an increase of 71 per cent on the previous quarter, in part due to more sales via Australian distributors. This continued the strong and sustained quarter-on-quarter sales growth delivered by SKN since it first listed on the ASX in January 2017.
SKN currently has three distinct product ranges: the market leading Soléo Organics 100% natural and organic sunscreen, the Elizabeth Jane Natural Cosmetic skincare range, and the McArthur range of natural therapeutic skin care products (for common skin conditions).
The December quarter saw the company execute on its growth strategy of delivering sustained sales growth, taking steps towards entering new markets and ongoing product development.
It’s worth noting here that SKN is an early stage play and investors should seek professional financial advice if considering this company for their portfolio.
New online channel and more bolsters Soléo sunscreen sales
SKN’s lead product is its Soléo organic sunscreen which was the focus of a website launch in December intended to drive sales.
The new e-commerce website allows direct online sales capability and is expected to not only boost sales of Soléo sunscreen but the McArthur range of skincare products as well. The new online sales website is available via the Skin Elements company website or via this direct link.
During the quarter, the company also expanded its production capacity with a 20,000 tube production run of the sunscreen which was delivered during the quarter to meet growing demand.
A look at SKN’s balance sheet
In the report the company has advised shareholders it has been taking a shrewd approach to capital expenditure across the business, and has been in the process of evaluating cash inflows and operational spend requirements.
With a current cash balance of $651,000 at quarter’s end, combined with receivables totalling $107,000 and inventory to the value of $375,000 it is in a reasonable cash position. It also has a loan facility in place, with access to up to $550,000 available as required.
With sales moving consistently in the right direction over the last 12 months, SKN will be looking to fortify its cash position as it works towards increasing revenue and expanding its distribution footprint beyond Australia and New Zealand, to Europe, North America and Asia. It plans to update the market of material progress on its expansion efforts in the coming months.
New board appointment
During the quarter SKN welcomed Phil Giglia to the board as an Independent Non-Executive Director after the passing of Mr David Humann.
Giglia is a chartered accountant with over 30 years’ experience in accounting and a strong depth of taxation expertise in SMEs. He is also a registered tax agent and company auditor.
He is the founder of Perth accountancy practice, Giglia & Associates which specialises in providing accountancy advice to high net worth clients.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
